Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: A multiple regression analysis with proxies of healthcare need

International Journal for Equity in Health

Volumn 4, Issue , 2005, Pages

  Ward, Paul R ^a   Noyce, Peter R ^b   St Leger, Antony S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; DISEASE ASSOCIATION; ETHNOLOGY; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; HEALTH CARE DELIVERY; HUMAN; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; PRESCRIPTION; PREVALENCE; REGISTER; UNITED KINGDOM;

EID: 15244341150     PISSN: 14759276     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-9276-4-3     Document Type: Article

References (75)

1. Goddard M, Smith P: Equity of access to health care services: theory and evidence from the UK. Soc Sci Med 2001, 53:1149-1162.
2. Whitehead M: The concepts and principles of equity and health. Int J Health Serv 1992, 22:429-445.
3. Williams A, Cookson R: Equity in health. In Handbook of Health Economics Edited by: Culyer AJ and Newhouse J. Amsterdam, Elsevier; 2000.
4. Ward PR, Noyce PR, St Leger AS: Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004, 58:89-96.
5. Tudor Hart J: The inverse care law. Lancet 1971, i:405-412.
6. Health D: National Service Frameworks for Coronary Heart Disease London, Stationary Office; 2000.
7. Rice N, Dixon P, Lloyd DC, Roberts D: Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. BMJ 2000, 320:284-288.
8. Lloyd DC, Scrivener G: Prescribing at the Primary Care Group level: census data and prescribing indicators. J Clin Pharm Therapeutics 2001, 26:93-101.
9. Majeed A, Cook DG, Evans N: Variations in general practice prescribing costs - implications for setting and monitoring prescribing budgets. Health Trends 1996, 28:52-55.
10. Morton-Jones T, Pringle M: Explaining variations in prescribing costs across England. BMJ 1993, 306:1731-1734.
11. Pringle M, Morton-Jones T: Using unemployment rates to predict prescribing trends in England. Br J Gen Pract 1994, 44:53-56.
12. Baxter C, Jones R, Corr L: Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998, 317:1134-1135.
13. Majeed A, Moser K, Maxwell R: Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000, 22:275-279.
14. Packham C, Pearson J, Robinson J, Gray D: Use of statins in general practices, 1996-8: cross sectional study. BMJ 2000, 320:1583-1584.
15. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D: Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999, 21:60-64.
16. Reid FDA, Cook DG, Whincup PH: Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002, 88:15-19.
17. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP: Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 2002, 88:159-162.
18. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A: Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001, 322:832.
19. Primatesta P, Poulter NR: Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000, 321:1322-1325.
20. Patel MG, Wright DJ, Gill PS, Jerwood D, Silcock J, Chrystyn H: Prescribing of lipid lowering drugs to South Asian patients: ecological study. BMJ 2002, 325:25-26.
21. Gibson A, Asthana S, Brigham P, Moon G, Dicker J: Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health & Place 2002, 8:47-60.
22. Wang TJ, Stafford RS: National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 1998, 158:1901-1906.
23. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489-497.
24. Bradshaw N, Fone DL, Walker R: Explaining variation in statin prescribing: a practice based analysis. Pharm J 1999, 263:R19.
25. Health D: The New NHS: Modern, Dependable. London, HMSO; 1998.
26. Health D: Primary Care Trusts, Establisging Better Services. London, NHS Executive; 1999.
27. Health D: Shifting the Balance of Power: Next Steps. London, The Stationary Office; 2002.
28. Peckham S, Taylor P: Public health and primary care. In Public Health for the 21st Century. New Perspectives on policy, participation and practice. Edited by: Orme J, Powell J, Taylor P, Harrison T and Grey M. Maidenhead, Open Universtity Press; 2003.
29. Ward PR, Noyce PR, St Leger AS: Developing prevalence-based prescribing units for analysing variations in general practitioner prescribing: a case study using statins. J Clin Pharm Ther 2003, 28:23-29.
30. Ward PR, Noyce PR, St Leger AS: Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England. Therapeutics and Clinical Risk Management 2005, 1:61-68.
31. Chapman SR: Prescribing information systems; making sense of primary care data. J Clin Pharm Therapeutics 2001, 26:235-239.
32. Majeed A, Evans N, Head P: What can PACT tell us about prescribing in general practice? BMJ 1997, 315:1515-1519.
33. Hopper S, Pierce P: Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract 1998, 15:S10-S13.
34. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM: Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998, 316:1430-1434.
35. Bedson J, Whitehurst T, Lewis M, Croft P: Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 2001, 51:1001-1003.
36. Steg PG, Iung B, Feldman LJ, Cokkinos D, Deckers J, Fox KAA, Keil U, Maggioni AP: Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart 2002, 88:20-24.
37. Group. EUROASPIREII: Liefstyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001, 22:554-572.
38. Frischer M, Chapman SR: Issues and Directions in Prescribing Analysis. In Medicines Management. Edited by: Panton R and Chapman SR. London, Pharmaceutical Press; 1998.
39. Bogle SM, Harris CM: Measuring prescribing: the shortcomings of the item. BMJ 1994, 308:637-640.
40. Unit PS: Defined Daily Doses, Prescribed Daily Doses and Average Daily Quantities Leeds, Prescribing Support Unit; 1997.
41. Organisation. WH: Guideline for Defined Daily Doses. Oslo, WHO Collaborating Centre for Drug Statistics; 1991.
42. Walley T, Roberts DJ: Average daily quantities: a tool for measuring prescribing volume in England. Pharmacoepidemiol Drug Safety 2000, 9:55-58.
43. Unit PS: Average Daily Quantities and STAR(97)-PUs Leeds, PSU; 2000.
44. Statistics ON: Key Statistics from General Practice. London, ONS; 1998.
45. Tunstall-Pedoe H: Cardiovascular diseases. In Oxford Textbook of Public Health. Volume 3. The Practice of Public Health. 3rd Edition edition. Edited by: Detels R, Holland W, McEwan J and Omenn GS. Oxford, Oxford Medical Publications; 1997.
46. Langham S, Normand C, Piercy J, Rose G: Cornary Heart Disease. In Health Care Needs Assessment. The Epidemiologically Based needs Assessment Reviews. Volume 1 edition. Edited by: Stevens A and Raftery J. Oxford, John Radcliffe Medical Press; 1994:341-378.
47. Unit JHS: Health Survey for England 1998 London, The Stationary Office; 1999.
48. Chaturvedi N, Fuller J: Ethnic differences in mortlaity from cardiovascular disease in the UK: do they persist in people with diabetes? J Epidemiol Community Health 1996, 50:137-139.
49. Foundation BH: Coronary Heart Disease Statistics. British Heart Foundation Database 2002. 2002.
50. Bhopal R: What is the risk of coronary heart disease in South Asians? A review of the UK research. J Public Health Med 2000, 22:375-385.
51. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KG, Harland J, Patel S, Ahmad N, Turner C, Watson B, Kaur D, Kulkarni A, Laker M, Tavridou A: Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999, 319:215-220.
52. Nazroo JY: The Health of Britain's Ethnic Minorities London, Policy Studies Institute; 1997.
53. Cooper H: Investigating socio-economic explanations for gender and ethnic inequalities in health. Soc Sci Med 2002, 54:693-706.
54. Mann JI, Marmot MG: Epidemiology of ischaemic heart disease. In Oxford Textbook of Medicine. Volume II. Second Edition edition. Edited by: Weatherall DJ, Ledingham JGG and Warrell DA. Oxford, Oxford Medical Publications; 1987.
55. Townsend P, Phillimore P, Beattie A: Health and Deprivation: Inequality and the North London, Croon Helm; 1988.
56. Whitehead M: The health divide: inequalities in health in the 1980s London, Health Education Authority; 1987.
57. Salomaa V, Miettinen H, Niemela M, Ketonen M, Mahonen M, Immonen-Raiha P, Lehto S, Vuorenmaa T, Koskinen S, Palomaki P, Mustaniemi H, Kaarsalo E, Arstila M, Torppa J, Kuulasmaa K, Puska P, Pyorala K, Tuomilehto J: Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI Register Study. J Epidemiol Community Health 2001, 55:475-482.
58. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, Tsevant J, Weinstein MC: The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997, 277:535-542.
59. Jousilahti P, Vartianen E, Tuomilehto J, Pekkanen J, Puska P: Effect of risk factors and changes in risk factors on coronary mortality in three cohorts of middle-aged people in eastern Finland. Am J Epidemiol 1995, 141:50-60.
60. Hope B: UK lags behind in fight against heart disease. BMJ 1999, 318:1229.
61. Davey-Smith G, Hart C, Blane D: Lifetime socioeconomic position and mortality: prospective observational study. BMJ 1997, 314:547-552.
62. Davey-Smith G: Down at heart - the meaning and implications of social inequalities in cardiovascular disease. J Roy Coll Physicians 1997, 31:414-424.
63. Suadicani P, Hein HO, Gyntelberg F: Socioeconomic status and ischaemic heart disease mortality in middle- aged men: importance of the duration of follow-up. The Copenhagen Male Study. Int J Epidemiol 2001, 30:248-255.
64. Lloyd DC, Harris CM, Clucas DW: Low income scheme index: a new deprivation scale based on prescribing in general practice. BMJ 1995, 310:165-169.
65. Majeed FA, Cook DG, Poloniecki J, Martin D: Using data from the 1991 census. BMJ 1995, 310:1511-1514.
66. Haynes RM, Lovett AA, Gale SH, Brainard JS, Bentham G: Evaluation of methods for calculating census health indicators for GP practices. Public Health 1995, 109:369-374.
67. Crayford T, Shanks J, Bajekal M, Langford S: Analysis from Inner London of deprivation payments based on enumeration districts rather than wards. BMJ 1995, 311:787-788.
68. Kerrison S, Macfarlane A: Official Health Statistics. An Unofficial Guide. London, Arnold; 2000.
69. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A: Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002, 88:25-29.
70. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation 2001, 103:38-44.
71. MacLeod MC, Finlayson AR, Pell JP, Findlay IN: Geographic, demographic, and socioeconomic variations in the investigation and management of coronary heart disease in Scotland. Heart 1999, 81:252-256.
72. Majeed FA, Cook D: Age and sex differences in the management of ischaemic heart disease. Public Health 1996, 110:7-12.
73. NHS Centre for Reviews and Dissemination: Cholesterol and coronary heart disease: screening and treatment. Effective Health Care Bulletin 41998, 1:.
74. Gardner K, Chapple A: Barriers to referral in patients with angina: qualitative study. BMJ 1999, 319:418-421.
75. Tod AM, Read C, Lacey A, Abbott J: Barriers to uptake of services for coronary heart disease: qualitative study. BMJ 2001, 323:214.